suMMARY Pentagastrin is rapidly removed from the circulation of the dog. It is excreted by the liver into the bile, largely in an inactivated form. Preliminary results indicate that it meets the same fate in man.
The synthetic pentapeptide pentagastrin has the same biological effects as gastrin and is widely used to stimulate gastric acid secretion in tests in man and in animals. The fate of gastrin in the body is not precisely known: Clendinnen, Davidson, Lemmi, Jackson, and Thompson (1970) have suggested that it is inactivated on passage through the kidney and we have recently shown it to be inactivated as it traverses the small bowel vascular bed. In contrast, pentagastrin is unaffected by the small bowel, but loses potency as it passes through the liver (Temperley, Stagg, and Wyllie, 1971) . In the present study the fate of pentagastrin in the liver has been investigated by experiments in anaesthetized dogs; pentagastrin is excreted into the bile, mainly in an inactive form.
Methods

PREPARATION OF DOGS
Twelve adult mongrel dogs of either sex weighing 9.3-16.8 kg (mean 13.1 kg) were anaesthetized by intravenous injection of pentobarbitone (25 mg/kg body weight). Anaesthesia was maintained by further hourly injections of 5 mg/kg. The trachea was intubated with a cuffed tube and the lungs were ventilated with air using a stroke volume of 20 ml/ kg body weight and a frequency of 25/minute.
A polythene cannula was tied into the left external jugular vein; through it infusions ofpentagastrin were given at a rate of 30 .g/kg/hr (15 ,ug/kg/hr Received for publication 22 July 1971. pentagastrin used was either the commercially available material (Peptavlon, ICI) or pentagastrin labelled with carbon-14 in the tryptophan residue, having a specific activity of 6 ,uCi/mg.
In 10 dogs cannulae were inserted into the portal and hepatic veins to sample blood entering and leaving the liver. The portal vein cannula was inserted via a splenic tributary, the spleen having been removed. The left anterior hepatic vein was cannulated by a non-occlusive technique described by Shoemaker, Walker, Van Itallie, and Moore (1959) .
To take blood samples the cannulae were first filled with blood from the animal, then 3 or 10 ml samples were simultaneously drawn from both veins at set times. The blood was placed in heparinized plastic tubes. The volume of blood so removed from the dog was immediately restored by injection of 0.15M sodium chloride solution and the cannulae were refilled with 0I15M sodium chloride solution containing 10 IU/ml of heparin.
In eight dogs the common bile duct was cannulated for collection of bile, and the cystic duct was ligated so that bile could not collect in the gallbladder during experiments. Bile was allowed to drain by gravity, and was usually collected before, during, and for one hour after infusion of pentagastrin.
At the end of four experiments using radioactive pentagastrin the livers were removed, washed free of blood, and weighed. Samples (about 5 g) were homogenized in 5 volumes of 0.25M sucrose using a glass Potter-Elvehjem homogenizer with a Teflon pestle. After centrifuging twice at 1,800 g for 10 minutes, radioactivity was measured in the supernatant.
BIOASSAY
The anaesthetized rat preparation of Smith, Lawrence, Colin-Jones, and Schild (1970) was used to measure pentagastrin in plasma and bile. Standard and test doses of pentagastrin were injected intra-venously into rats and the resultant production of gastric acid was measured. It was possible to assay as little as 20 ng of pentagastrin in this way.
MEASUREMENT OF RADIOACTIVITY
The radioactivity in duplicate samples of plasma, urine, bile and supernatant from liver homogenates was measured by conventional radioactive counting procedures. From these measurements we calculated the total radioactivity excreted in urine and bile, and in the livers at the end of the experiments. The total radioactivity in the extracellular fluid was also calculated in six experiments by assuming that one hour after ending the pentagastrin infusions the pentagastrin levels in plasma were equilibrated with those in the entire extracellular water. Extracellular body water was taken to be 200 ml/kg of body weight (Spector, 1956 minutes later. As shown in Fig. 1 the infusions produced plasma levels in the dog which could easily be measured by bioassay in the rat. Portal vein levels were measured in four dogs and were compared with those in the hepatic vein in two of them. The mean value attained in the portal vein at the end of 30-min infusions (146 ng/ml ± 14.1 SEM) was significantly higher (p < 0'005) than that in the hepatic vein (51.5 ng/ml ± 1.5 SEM). Further assays 10 and 20 minutes after stopping the infusion failed to detect pentagastrin in the hepatic vein; the levels must therefore have been less than 10 ng/ml. Rapidly declining levels were found in the portal vein. These experiments showed that pentagastrin was inactivated on passage through the liver, thus confirming our previous results (Temperley et al, 1971 ). They did not show what happened to the pentagastrin. It might have been metabolized to inactive derivatives which continued to circulate in the blood; it might have been taken up and stored in the liver; it might have been excreted in the bile either unchanged or as a derivative; or it might have suffered all these fates in varying proportion. To study this we carried out experiments with pentagastrin labelled with carbon-14.
LABELLED PENTAGASTRIN IN DOGS
In experiments on five dogs (experiments 4-8 of Table I ) 14C-labelled pentagastrin was infused for 30 min at 30 ,ug/kg/hr and blood samples were taken from portal and hepatic veins at intervals. The results were calculated in terms of disintegrations per minute per millilitre of plasma since it was recognized that pentagastrin might be broken down in the body and that some of the label might represent metabolites ahd not the infused material. Comparison of radioactivity in plasma and in successive washings of erythrocytes with OI5M NaCI showed that little, if any, of the label entered the erythrocytes. The plasma levels therefore represented all the pentagastrin in the blood.
The experiments all showed very similar results; mean values are shown in Figure 2 . Standard errors of these means are shown, for clarity, only for selected values. Five minutes after starting an infusion radioactivity could be detected in both blood vessels: that in the portal vein always greatly exceeded that in the hepatic vein during the infusion. By 30 min the pentagastrin levels had almost ceased to rise, indicating that a steady state was being reached and that infusion of the labelled compound was approximately matched by its removal from the circulation. A t test on paired values attained at the end of the infusions (25 and 30 min) indicated a significant difference between hepatic and portal vein levels (p < 0.02 in each case). The hepatic vein Assuming that one hour after the end of an infusion the radioactivity circulating in the plasma was distributed through the entire extracellular water we calculated for six experiments the percentage of the administered dose which remained in the dogs. Table I shows that the results lay between 20 and 33% (mean 24.4%). The bulk of the radioisotope was found in the bile. This amounted to 28-80% (mean 47.0%) of the total dose administered. contained label most of the isotope was found in the bile canaliculi. Thus hepatic excretion of the 14C-label accounted for about 60% of the administered isotope. Urinary excretion was also measured in six experiments, and represented only a small percentage of the total dose. Bioassay of labelled pentagastrin was carried out on bile from six dogs, using the anaesthetized rat preparation (Smith et al, 1970) . Table I shows that biological activity was detected in all six cases but the activity was lower than would be expected from the radioactivity measurements; bioactivity averaged 16 % of the administered pentagastrin as compared with 45% for radioactivity. This difference was not an artefact, since (1) 14C-labelled and unlabelled pentagastrin had very similar potencies when assayed in the anaesthetized rat, and (2) pentagastrin added to dog bile and injected into rats gave the predicted response. It was concluded that pentagastrin was excreted either as a derivative of lower biological potency or as a mixture of an inactive derivative and unchanged pentagastrin.
EXPERIMENTS IN MAN
It is likely that pentagastrin meets a similar fate in man. We have not, of course, infused pentagastrin in man at 30 gg/kg/hr, nor have we given to man pentagastrin labelled with carbon-14. Two patients volunteered to have unlabelled pentagastrin (Peptavlon, ICI; 6 ug/kg subcutaneously) with their premedication. Both had been shown to have functioning gallbladders containing stones, and subsequently underwent cholecystectomy. The bile in their gallbladders was injected into rats and caused gastric secretion while bile from similar patients who had not received pentagastrin showed no such activity.
Discussion
The experiments with unlabelled pentagastrin showed that pentagastrin was inactivated by the dog liver in vivo; those with the labelled compound proved that this inactivation was the result of both excretion and metabolism of the drug. These experiments might be criticized because they employed a high rate of administration of pentagastrin: 30 jig/ kg/hr is five times the dose which has usually been given to man by continuous infusion. We do not think that the fate of the drug would be different at lower dose rates because the single experiment we made using a dose rate of 15 gg/kg/hr yielded a result quite similar to those of the other seven experiments.
In the experiments for which we have complete data (Table I) it was possible to account for 73 to 106% of the administered isotope by considering radioactivity excreted in bile and urine during the experiment and that remaining in the liver and extracellular fluid at the end. This indicates that the liver is the major site of pentagastrin metabolism in the dog.
While there is no proof that pentagastrin is similarly handled by human beings and by dogs, the limited data available from man suggest that this is so. Gastric secretagogue activity could only be detected in human bile by the injection of 0.5 ml into the rat assay preparation. This large volume had toxic effects on the rats, so the responses could not be quantitated. It was, however, qualitatively shown that biologically active pentagastrin was excreted by the human liver following a subcutaneous injection of the drug. This suggests that the fate of pentagastrin in man is similar to that in the dog.
Our results are of particular interest in relation to the fate of the natural hormone gastrin. Gastrin and pentagastrin have similar actions in the body, but they meet different fates. Pentagastrin, as we have shown, is eliminated by the liver but there is no evidence of selective inactivation of gastrin by this organ. Indeed, gastrin appears to be inactivated by the kidneys (Clendinnen et al, 1970 ) and the gut (Temperley et al, 1971 ). This marked dissimilarity in the fate of the two compounds must be considered in relation to the relative potency of gastrin and pentagastrin in stimulating gastric acid secretion. The relative efficiencies of the inactivation mechanisms must at least partly determine the apparent potency ratio.
The biological activity of gastrin and pentagastrin resides in the C-terminal tetrapeptide sequence which occurs in both molecules (Morley, Tracy, and Gregory, 1965) . The rest of the gastrin molecule (residues 1-13) has not had any function attributed to it. Our results show that it is not redundant: in some way it protects the active tetrapeptide (residues 14-17) from excretion and metabolism by the liver. Perhaps the complete gastrin molecule (molecular weight 2100) is too large to enter hepatocytes. Whatever the explanation of the differing fates of gastrin and pentagastrin it is clear that one must not assume that the two compounds are treated similarly in the body.
